Bifogade filer
Board member of Biovica resigns at own request
Kurs
+0,74%
Likviditet
0,11 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-06-17 | 08:00 | Bokslutskommuniké 2026 |
| 2026-03-18 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2025-12-18 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2025-09-16 | N/A | Årsstämma |
| 2025-09-11 | 08:00 | Kvartalsrapport 2026-Q1 |
| 2025-06-18 | 08:00 | Bokslutskommuniké 2025 |
| 2025-03-13 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2024-12-12 | - | Kvartalsrapport 2025-Q2 |
| 2024-09-18 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2024-09-17 | - | Årsstämma |
| 2024-09-12 | - | Kvartalsrapport 2025-Q1 |
| 2024-07-15 | - | Extra Bolagsstämma 2025 |
| 2024-06-18 | - | Bokslutskommuniké 2024 |
| 2024-03-14 | - | Kvartalsrapport 2024-Q3 |
| 2023-11-28 | - | Kvartalsrapport 2024-Q2 |
| 2023-09-06 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2023-09-06 | - | Kvartalsrapport 2024-Q1 |
| 2023-09-05 | - | Årsstämma |
| 2023-06-21 | - | Bokslutskommuniké 2023 |
| 2023-05-17 | - | Extra Bolagsstämma 2024 |
| 2023-03-16 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-15 | - | Kvartalsrapport 2023-Q2 |
| 2022-11-07 | - | Extra Bolagsstämma 2022 |
| 2022-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2022-08-31 | - | Årsstämma |
| 2022-08-31 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-16 | - | Bokslutskommuniké 2022 |
| 2022-03-15 | - | Kvartalsrapport 2022-Q3 |
| 2021-12-01 | - | Kvartalsrapport 2022-Q2 |
| 2021-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2021-08-31 | - | Årsstämma |
| 2021-08-31 | - | Kvartalsrapport 2022-Q1 |
| 2021-06-17 | - | Bokslutskommuniké 2021 |
| 2021-03-18 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-03 | - | Kvartalsrapport 2021-Q2 |
| 2020-08-28 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2020-08-27 | - | Årsstämma |
| 2020-08-27 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-12 | - | Bokslutskommuniké 2020 |
| 2020-03-12 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-05 | - | Kvartalsrapport 2020-Q2 |
| 2019-08-30 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2019-08-29 | - | Årsstämma |
| 2019-08-29 | - | Kvartalsrapport 2020-Q1 |
| 2019-06-14 | - | Bokslutskommuniké 2019 |
| 2019-05-02 | - | Extra Bolagsstämma 2020 |
| 2019-03-21 | - | Kvartalsrapport 2019-Q3 |
| 2018-12-13 | - | Kvartalsrapport 2019-Q2 |
| 2018-08-31 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2018-08-30 | - | Årsstämma |
| 2018-08-30 | - | Kvartalsrapport 2019-Q1 |
| 2018-06-15 | - | Bokslutskommuniké 2018 |
| 2018-03-21 | - | Kvartalsrapport 2018-Q3 |
| 2017-12-19 | - | Kvartalsrapport 2018-Q2 |
| 2017-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
| 2017-08-31 | - | Årsstämma |
| 2017-08-31 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-14 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Biovica today announces that board member Ulf Jungnelius has resigned from the board at his own request, with immediate effect. Personal reasons are behind the decision.
"Due to my current situation, I am unable to fully participate in the board's work in the way I would like. Therefore, I have chosen to end my assignment," said Ulf Jungnelius.
"We have great respect for Ulf's decision and thank him for his valuable contributions to Biovica," said Lars Holmqvist, Chairman of the Board of Biovica.
After Ulf Jungnelius' departure, the board will consist of six members, thus meeting the requirements of the company's articles of association
Contact
Anders Rylander, CEO
Phone: +46 76 666 16 47
E-mail: anders.rylander@biovica.com
Anders Morén, CFO
Phone: +46 73 125 92 46
E-mail: anders.moren@biovica.com
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com